Liraglutide's metabolic benefits for prediabetes are sex- and reproductive status-dependent in HHTg rats
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) and prediabetes are growing global health concerns, often preceding Type 2 Diabetes (T2D). Current treatments, including GLP-1 receptor agonists (GLP-1 RAs), show variable efficacy, suggesting individual factors like sex and reproductive status may influence their therapeutic impact. Understanding these nuances is crucial for optimizing treatment strategies and personalizing care, especially given the distinct metabolic profiles observed between sexes and across different reproductive stages.
Study Design
Researchers administered liraglutide 0.2 mg/kg/day subcutaneously (SC) for 8 weeks to male, female, and ovariectomized (OVX) female hereditary hypertriglyceridemic (HHTg) rats, serving as a prediabetic model. The study assessed the effects on metabolic disorders, including glucose tolerance, lipid metabolism, visceral adiposity, and hepatic triacylglycerol (TAG) accumulation. Hepatic gene expression related to lipogenesis, fatty acid/lipid metabolism, and fibrosis was analyzed using qPCR to elucidate underlying mechanisms.
Results
Liraglutide consistently improved glucose tolerance across all HHTg rat groups. Notably, female and OVX female rats exhibited a significantly stronger effect on lipid metabolism and visceral adiposity compared to males. In contrast, males showed no changes in hepatic triacylglycerol (TAG) accumulation. Liraglutide partially reversed several ovariectomy-induced metabolic detriments, including increased body weight, visceral obesity, and impaired glucose tolerance. Compared with males, female and OVX female rats demonstrated more significant changes in hepatic gene expression, specifically in genes involved in lipogenesis (Scd-1, Srebp1, Pparγ), fatty acid and lipid metabolism (Pparα, Hmgcr, Srebp2), and fibrosis (Tgfβ), suggesting an improved hepatic lipid metabolic profile.
Females of fertile age showed greater improvements in insulin sensitivity, reductions in ectopic lipid accumulation, and overall improvements in lipid metabolism.
Key Findings
- Liraglutide improved glucose tolerance in all prediabetic HHTg rats.
- Female and OVX female rats showed stronger improvements in lipid metabolism and visceral adiposity than males.
- Males exhibited no changes in hepatic triacylglycerol (TAG) accumulation with liraglutide treatment.
- Liraglutide partially reversed ovariectomy-induced increases in body weight, visceral obesity, and impaired glucose tolerance.
- Fertile-aged females showed greater improvements in insulin sensitivity and reductions in ectopic lipid accumulation.
Why It Matters
Liraglutide's efficacy in prediabetes appears highly dependent on sex and reproductive status, suggesting a need for personalized treatment approaches. This research highlights that women, particularly those of fertile age, may derive greater benefits from GLP-1 RA therapy for conditions like MASLD and visceral obesity, even before diabetes onset. For biohackers and clinicians, this implies that dosing strategies, monitoring protocols, and expected outcomes for GLP-1 RAs like liraglutide might need to be tailored based on a patient's sex and reproductive stage. Further research is needed to translate these preclinical findings into human clinical protocols, but it opens avenues for optimizing GLP-1 RA use in diverse populations.
liraglutide
prediabetes
masld
sex-differences
animal-study
glp-1-agonist